Propafenone and sotalol use in the treatment of atrial fibrillation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atrial fibrillation (AF) is one of the most common type of cardiac arrhythmias requiring treatment and associated with an increased rate of hospitalizations and deaths. The class 1C antiarrhythmic drugs propafenone and class III sotalol are more commonly used to treat patients with AF. The choice of the most effective and safe drug in particular clinical situation is an important task for a practitioner. The article provides an overview of propafenone and sotalol use for planned therapy in order to maintain sinus rhythm and propafenone to restore the rhythm in case of AF paroxysm.

Full Text

Restricted Access

About the authors

Vladimir L. Doshchitsin

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Dr. med. habil., professor, professor of the Department of cardiology of the Faculty of additional professional education

Andrey V. Syrov

Consultative and Diagnostic Center No. 6 of the Department of Healthcare of Moscow; Peoples' Friendship University of Russia

PhD in Medicine, associate professor of the Department of general medical practice of the Medical Institute; head of the Department of cardiology

References

  1. Zulkifly H., Lip G., Lane D. Epidemiology of atrial fibrillation. Int J. Clin Pract. 2018; 72(3): e 13070. https://dx.doi.org/10.1111/ijcp.13070.
  2. Клинические рекомендации. Фибрилляция и трепетание предсердий у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Ассоциация сердечно-сосудистых хирургов России. 2020. Рубрикатор клинических рекомендаций Минздрава России. ID: 382. Доступ: https://cr.minzdrav.gov.ru/schema/382_1 (дата обращения - 01.10.2022).
  3. European Society of Cardiology. 2020 guidelines for of atrial fibrillation. ESC clinical practice guidelines. URL: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management (date of access - 01.10.2022).
  4. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J. Clin Pharmacol. 1984; 24(4): 129-47. https://dx.doi.org/10.1002/j.1552-4604.1984.tb01822.x.
  5. RxList. Propaphenone. URL: https://www.rxlist.com/consumer_propafenone_rythmol_rythmol_sr/drugs-condition.htm (date of access - 01.10.2022).
  6. Официальные инструкции по применению лекарственных препаратов с МНН пропафенон. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/(дата обращения - 01.10.2022).
  7. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9(9): CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub5.
  8. Lafuente-Lafuente C., Longas-Tejero M., Bergmann J., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012; 5: CD005049. https://dx.doi.org/10.1002/14651858.CD005049.pub3.
  9. RxList. Sotalol. URL: https://www.rxlist.com/consumer_sotalol_betapace/drugs-condition.htm (date of access - 01.10.2022).
  10. Официальные инструкции по применению лекарственных препаратов с МНН соталол. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/(дата обращения - 01.10.2022).
  11. Finks S.W., Rogers K.C., Manguso A.H. Assessment of sotalol prescribing in a community hospital: Opportunities for clinical pharmacist involvement. Int J. Pharm Pract. 2011; 19(4): 281-86. https://dx.doi.org/10.1111/j.2042-7174.2011.00094.x.
  12. Caldeira D., David C., Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012; 105(4): 226-38. https://dx.doi.org/10.1016/j.acvd.2011.11.005.
  13. Carlsson J., Miketic S., Windeler J. et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am Coll Cardiol. 2003; 41(10): 1690-96. https://dx.doi.org/10.1016/s0735-1097(03)00332-2.
  14. Hohnloser S., Kuck K., Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000; 356(9244): 1789-94. https://dx.doi.org/10.1016/s0140-6736(00)03230-x.
  15. Karamichalakis N., Letsas K., Vlachos K. et al. Managing atrial fibrillation in the very elderly patient: Challenges and solutions. Vasc Health Risk Manag. 2015; 1 1: 555-62. https://dx.doi.org/10.2147/VHRM.S83664.
  16. McNamara R.L., Tamariz L.J., Segal J.B., Bass E.B. Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003; 139(12): 1018-33. https://dx.doi.org/10.7326/0003-4819-139-12-200312160-00012.
  17. Olshansky B., Rosenfeld L.E., Warner A.L. et al.; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J. Am Coll Cardiol. 2004; 43(7): 1201-8. https://dx.doi.org/10.1016/j.jacc.2003.11.032.
  18. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl J. Med. 2008; 358(25): 2667-77. https://dx.doi.org/10.1056/NEJMoa0708789.
  19. Van Gelder I.C., Hagens V.E., Bosker H.A. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl J. Med. 2002; 347: 1834-40. https://dx.doi.org/10.1056/NEJMoa021375.
  20. Wyse D.G. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. J. Interv Card Electrophysiol. 2009; 25(1): 25-29. https://dx.doi.org/10.1007/s10840-008-9329-8.
  21. Kerzner R., Rich M. Atrial fibrillation in the elderly. J. Ger Cardiol. 2005; 2(2): 68-73.
  22. Kirchhof P., Camm A.J., Goette A. et al.; on behalf of the EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl J. Med. 2020; 383(14): 1305-16. https://dx.doi.org/10.1056/NEJMoa2019422.
  23. Alboni P., Botto G.L., Baldi N. et al. Outpation treatment of recent-onset atrial fibrillation with the «pill in pocket» approach. N. Engl J. Med. 2004; 351(23): 2384-91. https://dx.doi.org/10.1056/NEJMoa041233.
  24. Antonelli D., Darawsha A., Rimbrot S. et al.
  25. Azpitarte J., Alvarez M., Baun O. et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997; 18(10): 1649-54. https://dx.doi.org/10.1093/oxfordjournals.eurheartj.a015146.
  26. Boriani G., Capucci A., Lenzi T. et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest. 1995; 108(2): 355-58. https://dx.doi.org/10.1378/chest.108.2.355.
  27. Boriani G., Biffi M., Capucci A. et al. Oral loading with propafenone: A placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol. 1998; 21(11Pt2): 2465-69. https://dx.doi.org/10.1111/j.1540-8159.1998.tb01202.x.
  28. Blanc J., Voinov C., Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J. Cardiol. 1999; 84(9): 1029-32. https://dx.doi.org/10.1016/s0002-9149(99)00493-2.
  29. Botto G., Capucci A., Bonini W. at al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: Comparison of two regimens. Int J. Cardiol. 1997; 58(1): 55-61. https://dx.doi.org/10.1016/s0167-5273(96)02841-0.
  30. Capucci A., Villiani G., Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo - controlled multicentred study. Int J. Cardiol. 1999; 68(2): 187-96. https://dx.doi.org/10.1016/s0167-5273(98)00363-5.
  31. Deneer V., Borgh M., Kingma J. et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci. 2004; 26(2): 66-78. https://dx.doi.org/10.1023/b:phar.0000018593.02291.c0.
  32. Fresco C., Proclemer A., Pavan A. et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996; 19(5): 409-12. https://dx.doi.org/10.1002/clc.4960190515.
  33. Khan I. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J. Am Coll Cardiol. 2001; 37(2): 542-47. https://dx.doi.org/10.1016/s0735-1097(00)01116-5.
  34. Martignani C., Diemberger I., Ziacchi M. et al. Oral loading of propafenone: Restoring its role before restoring rhythm. Europace. 2017; 19(11): 1903. https://dx.doi.org/10.1093/europace/euw264.
  35. Meinertz T., Lip G., Lombardi F. et al.; ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J. Cardiol. 2002; 90(12): 1300-6. https://dx.doi.org/10.1016/s0002-9149(02)02867-9.
  36. Porterfield J., Porterfield L. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J. Cardiol. 1989; 63(1): 114-16. https://dx.doi.org/10.1016/0002-9149(89)91091-6.
  37. Satullo G., Arrigo F., Cavallaro L. et al.
  38. Лукьянова И.Ю., Кузнецов А.В., Комарницкий В.М., Козырева А.Г. Изучение эффективности и безопасности препаратов для медикаментозной кардиоверсии у больных с пароксизмальной формой фибрилляции предсердий на догоспитальном этапе. Скорая медицинская помощь. 2017; 18(4): 43-47. [Lukyanova I.Yu., Kuznetsov A.V., Komarnitsky V.M., Kozyreva A.G. To study the efficacy and safety of drugs for medical cardioversion in patients with paroxysmal atrial fibrillation at the prehospital stage. Skoraya meditsinskaya pomoshch' = Emergency Medical Care. 2017; 18(4): 43-47 (In Russ.)]. https://dx.doi.org/10.24884/2072-6716-2017-18-4-43-47. EDN: ZXPLQJ.
  39. Фомина И.Г., Тарзиманова А.И., Вертлужский А.В. с соавт. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» - открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005; 4(4): 66-69. [Fomina I.G., Tarzimanova A.I., Vertluzhsky A.V. et al. Propafenone in the restoration of sinus rhythm in patients with persistent atrial fibrillation. PROMETHEUS is an open, multicentre, pilot study in the Russian Federation. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2005; 4(4): 66-69 (In Russ.)]. EDN: HWESHN.
  40. Antonelli D., Freedberg N.A., Feldman A. at al.
  41. Capucci A., Boriani G. Intravenous administration of propafenone. J. Am Coll Cardiol. 1992; 19(6): 1368-69. https://dx.doi.org/10.1016/0735-1097(92)90350-v.
  42. Cointe R., Metge M., Bru P. at al.
  43. Carerj S., Cavalli G., Magazu A. at al.
  44. Goy J., Metrailler J., Humair L., de Torrente A. Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J. 1991; 122(6): 1788-90. https://dx.doi.org/10.1016/0002-8703(91)90306-3.
  45. Haefeli E.W., Vozeh S., Ha H.R., Follath F. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther. 1990; 48(3): 245-54. https://dx.doi.org/10.1038/clpt.1990.146.
  46. Liguori A., di Ieso N., D'Armiento F. et al. Intravenous propafenone for suppression of symptomatic atrial fibrillation and atrial flutter in a first aid hospital. Riv Eur Sci Med Farmacol. 1992; 14(4): 229-32.
  47. Madonia S., De Simone M., Brai G. et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: A randomized trial. Ital Heart J. 2000; 1(7): 475-79.
  48. Margheri M., Fradella G., Maioli M. et al.
  49. Velazquez Rodriguez E., Cancino Rodriguez C., Arias Estrada S. et al.
  50. Zadura M., Grossmann G., Modrzewska A. et al.
  51. Тарасов А.В., С.А.Косых С.А., Бушуева Е.В. с соавт. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019; 21(1): 81-86. [Tarasov A.V., S.A. Kosykh S.A., Bushueva E.V. et al. Comparison of the effectiveness of injectable forms of antiarrhythmic drugs propafenone and amiodarone during pharmacological cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019; 21(1): 81-86 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2019.1.190286. EDN: ZFHBML.
  52. Antman E.M., Beamer A.D., Cantillon C. et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J. Am Coll Cardiol. 1988; 12(4): 1005-11. https://dx.doi.org/10.1016/0735-1097(88)90468-8.
  53. Bellandi F., Simonetti I., Leoncini M. et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J. Cardiol. 2001; 88(6): 640-45. https://dx.doi.org/10.1016/s0002-9149(01)01806-9.
  54. Fetsch T., Bauer P., Engberding R. et al.; Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J. 2004; 25(16): 1385-94. https://dx.doi.org/10.1016/j.ehj.2004.04.015.
  55. Kowey P.R., Yannicelli D., Amsterdam E.; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J. Cardiol. 2004; 94(5): 663-65. https://dx.doi.org/10.1016/j.amjcard.2004.05.038.
  56. Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопастность применения пропафенона (Пропанорма®] и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне АГ ИБС и ХСН с сохраненной систолической функцией ЛЖ. Многоцентровое открытое рандомизированное, проспективное, сравнительное исследование ПРОСТОР Российский кардиологический журнал. 2010; 15(4): 56-72. [Miller O.N., Starichkov S.A., Pozdnyakov Yu.M. et al. Efficacy and safety of propafenone (Propanorm®) and amiodarone (Cordarone®) in patients with atrial fibrillation on the background of hypertension, coronary artery disease and chronic heart failure with preserved LV systolic function. Multicenter, open, randomized, prospective, comparative study PROSTOR. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2010; 15(4): 56-72 (In Russ.)]. EDN: MUENJV.
  57. Gomes J.A., Ip J., Santoni-Rugiu F. et al. Oral d, l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J. Am Coll Cardiol. 1999; 34(2): 334-39. https://dx.doi.org/10.1016/s0735-1097(99)00213-2.
  58. Somberg J., Molnar J. Sotalol versus amiodarone in treatment of atrial fibrillation. J. Atr Fibrillation. 2016; 8(5): 1359. https://dx.doi.org/10.4022/jafib.1359.
  59. Singh B.N., Singh S.N., Reda D.J. et al.; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N. Engl J. Med. 2005; 352(18): 1861-72. https://dx.doi.org/10.1056/NEJMoa041705.
  60. Waldo A., Camm A., deRuyter H. et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996; 348(9019): 7-12. https://dx.doi.org/10.1016/s0140-6736(96)02149-6.
  61. Zimetbaum P.J., Josephson M.E. Amiodarone versus sotalol for atrial fibrillation. N. Engl J. Med. 2005; 353(6): 627-30; author reply 627-30.
  62. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18(1): 5-66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbid pathology in clinical practice. Algorithms for diagnosis and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019; 18(1): 5-66 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2019-1-5-66. EDN: YXKKAP
  63. Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E. et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J. Cardiol. 2007; 99(12): 1721-25. https://dx.doi.org/10.1016/j.amjcard.2007.01.059.
  64. Kosior D.A., Kochanowski J., Scisto P. et al. Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J. 2009; 16(6): 521-27.
  65. Balla I., Petrela E., Kondili A. et al. Pharmacological conversion of recent atrial fibrillation: A randomized, placebo-controlled study of three antiarrhythmic drugs. Anadolu Kardiyol Derg. 2011; 11(7): 600-6. https://dx.doi.org/10.5152/akd.2011.162.
  66. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995; 92(9): 2550-57.
  67. Lardoux H., Maison Blanche P., Marchand X. et al.
  68. Bellandi F., Dabizzi R.P., Niccoli L. et al.
  69. Chimienti M., Cullen M.T. Jr, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the Flecainide and Propafenone Italian Study Investigators. Am J. Cardiol. 1996; 77(3): 60A-75A. https://dx.doi.org/10.1016/s0002-9149(97)89119-9.
  70. Gulizia M., Mangiameli S., Orazi S. et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial Arrhythmias (PITAGORA) trial. Am Heart J. 2008; 155(1): 100-7, 107.e1. https://dx.doi.org/10.1016/j.ahj.2007.08.033.
  71. Kochiadakis G.E., Igoumenidis N.E., Marketou M.E. et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: A comparative, placebo controlled study. Heart. 2000; 84(3): 251-57. https://dx.doi.org/10.1136/heart.84.3.251.
  72. Niu F., Huang C.X., Jiang H. et al.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies